Paragon Biosciences is an investor and incubator growing and building the biomedical innovations started by Jeff Aronin. It is committed to partner with leading companies in biotechnology for quality health progress in enabling people to live healthily. The mode of operation and the guiding principle is the centeredness to the needs of the patients and understanding the science surrounding a particular medical condition. Once that is done, the next step is to establish a company that will address the emerging and unmet conditions. This model drives the company more successful in developing drugs that speed the approval of significant medications. According to Paragon Biosciences, more than 6,000 diseases have not been placed with any treatment and their commitment is to work hard to reduce that fact. They are dedicated to developing companies that have discipline and strategies that target a particular clinic area more appropriately. Some of the companies that have been developed in line with this include Castle Creek, Harmony Biosciences, Decade, and Precision BP (http://askreporter.com/2018/02/jeff-aronin-delevopes-paragon-biosciences/). All have different areas of approach and target, and they give their best depending on the assignment upon them.
Jeff Aronin is the chief executive officer and chair of Paragon Biosciences. Jeff is a well-established biotechnology and healthcare entrepreneur for more than 20 years. He has expertise in that field where he gives his best to build more well known incubator and investor biotechnology companies. Jeff’s career is not an accident but a passion he has always had in healthcare. He grew up in his career with a great passion for science and bringing up great companies. In 2000, Jeff became the chief executive officer and founder of Ovation Pharmaceuticals Inc. While at the company, Jeff had great strategies to bring appropriate medicines to the patients by understanding their needs and focusing of the concerned teams to ensure that the medicines were approved. The company was however purchased later in 2009. Jeff Aronin has served in Paragon Biosciences for more than ten years with a critical role and focus on developing medicines that are significant to the patients. Through his work, much of technologies and medicines have been approved. Jeff is much confident about the company and anticipates more growth through adherence to their core values and mission to meet their goals.